The European Commission, in conjunction with the Organization for Economic Co-operation and Development, has released its Health at a Glance: Europe 2018 report which highlights the need for and value of generic and biosimilar products.
The European Commission, in conjunction with the Organization for Economic Co-operation and Development, has released its Health at a Glance: Europe 2018 report.
The report highlights the need for and value of generic and biosimilar products to reducing wasteful spending in healthcare systems. “After inpatient and outpatient care, pharmaceuticals represent the third largest item of healthcare spending, accounting for a sixth of health expenditure in the [European Union] in 2016,” the authors note.
Additionally, the report notes that nearly one-fifth of health spending is considered “wasteful,” and could be reduced or eliminated without undermining health system performance or quality. Reducing spending is particularly important when one considers that as much as 9.6% of European Gross Domestic Product is directed to healthcare.
In order to address wasteful pharmaceutical spending, the report describes 4 approaches: ensure value for money in selection, coverage, pricing, and procurement; fully exploit potential savings from generics and biosimilars; improve adherence to treatment, optimize packaging, and reduce waste; and promote rational prescribing while curbing overuse.
Specifically, biologics represent one of the most rapidly growing segments of the pharmaceutical market; it is estimated that biologics will increase from 25% of global pharmaceutical sales (by value) in 2017 to 31% in 2024. While biosimilars have been available in Europe for more than 10 years with 40 plus biosimilar products available in 15 different biologic classes, market penetration remains low. However, opportunities for further savings are substantial, as many major patent expiries are anticipated between 2018-2024.
The report explains that, across Europe, there are significant differences in policy approaches to biosimilar pricing and reimbursement, as well as stakeholder incentives for biosimilar use and education around the products. A recent study conducted across 20 EU Member States, Iceland, Norway, Russia, and Serbia, found that many biosimilars were not uniformly accessible across Europe. Significantly, the study found that Germany was the only country in which all approved biosimilars were available and funded.
In certain countries across Europe, incentives exist for physicians to prescribe biosimilars. In France, physicians are encouraged to prescribe at least 20% insulin glargine biosimilars in ambulatory care. Similarly, in Belgium, biosimilars are incorporated into physicians’ quotas for prescribing low-cost medications, and providers are encouraged to prescribe at least 20% biosimilars specifically for treatment-naïve patients.
In terms of potential savings from biosimilars, estimates have been substantial. In 2016, it was estimated that biosimilars could save up to €100 billion ($113 billion) by 2020 in the 5 most inhabited countries in the EU (Germany, France, Italy, Spain, and the United Kingdom) and the United States. The report also stresses the importance of promoting biosimilar uptake as a way to drive savings; however, it notes that “it is the market entry of biosimilars that promotes price competition,” as the correlation between biosimilar market share and price reductions is weak, suggesting the existence of barriers to effective competition.
Recently, Portugal has implemented financial incentives for pharmacies to encourage dispensing of lower-price medicines, including defining target market shares for biosimilar versions of infliximab, etanercept, and rituximab. In the Netherlands, there are limitations on the prescribing of reference products as part of agreements reached between insurance companies and hospitals, though the report noted that budget constraints within hospitals already provide incentives for the use of biosimilars.
Interestingly, substitution rules are also of importance in influencing biosimilar uptake in Europe. Most countries, with the exception of Estonia, France, Latvia, and Poland, do not allow unrestricted substitution of biologics at the point of dispensing. In France, draft legislation was introduced in 2017 permitting the substitution of biosimilars, but it is limited to initiating treatment in biologic-naïve patients, or to ensuring continuity for patients previously dispensed a biosimilar.
The FDA has not yet published a final guideline regarding interchangeability that allows for pharmacy-level substitution, though it is of note that most biosimilar products approved in the US to date are administered subcutaneously or as infusions, and not dispensed at the pharmacy level.
“In all approaches to reducing waste, stakeholder engagement and effective communication are critical. Prescribers and patients need to understand the value offered by generics and biosimilars, and be adequately reassured as to their equivalence and safety,” write the report’s authors. The report concluded by encouraging development and disbursement of guidelines and protocols that allow for discussion, engagement, and support for rational decision-making around reducing waste in pharmaceutical spending.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.